Abstract
Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Current Drug Delivery
Title:Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Volume: 11 Issue: 4
Author(s): Meenu Grover and Puneet Utreja
Affiliation:
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Abstract: Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Export Options
About this article
Cite this article as:
Grover Meenu and Utreja Puneet, Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review, Current Drug Delivery 2014; 11 (4) . https://dx.doi.org/10.2174/1567201811666140118225021
DOI https://dx.doi.org/10.2174/1567201811666140118225021 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes
Current Diabetes Reviews Transition of Care for Patients with Diabetes
Current Diabetes Reviews Pancreas Development and β-Cell Differentiation of Embryonic Stem Cells
Current Medicinal Chemistry Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Perforated One Anastomosis Gastric Bypass, How we Managed and Review of Literature
New Emirates Medical Journal Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry In Vivo and In Vitro Evaluation of the Therapeutic Potential of Some Turkish Scorzonera Species as Wound Healing Agent
Current Pharmaceutical Design Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Design The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Biology and Regulatory Roles of Nuclear Lamins in Cellular Function and Dysfunction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot topic:Current Hypertension Reviews, Hot Topics “Obesity, Hypertension, and the Metabolic Syndrome” (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Bone Metabolism and Histomorphometric Changes in Murine Models Treated with Sclerostin Antibody: A Systematic Review
Current Drug Targets Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions
Current Diabetes Reviews Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic Cardiopulmonary Bypass
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry